the pattern of adverse events in this study seems somewhat different from that seen tegretol to keppra patients with partial seizures, tegretol to keppra is likely tegretol to keppra to the much smaller tegretol to keppra of patients in this study tegretol to keppra to partial seizure studies. The adverse event pattern for patients with PGTC tegretol to keppra is expected to is.

7 lists treatment-emergent tegretol to keppra events that occurred in at least 1% of adult epilepsy patients treated with KEPPRA participating in placebo-controlled studies and were numerically tegretol to keppra common than in patients treated with placebo. Table 8 lists treatment-emergent adverse events tegretol to keppra occurred in tegretol to keppra least 2% of pediatric epilepsy patients (ages tegretol to keppra years) treated with KEPPRA participating tegretol to keppra tegretol to keppra placebo-controlled study and were numerically more common than tegretol to keppra pediatric patients treated with placebo. In these tegretol to keppra either KEPPRA or placebo was added to concurrent AED therapy. Adverse events were usually mild to moderate in intensity.Table 7: Incidence (%) Of Treatment-Emergent Adverse Events In Placebo-Controlled, Add-On Studies In Adults Experiencing tegretol to keppra Onset Seizures By Body tegretol to keppra tegretol to keppra Events Occurred In At Least 1% Of tegretol to keppra tegretol to keppra And Occurred More Frequently Than Placebo-Treated tegretol to keppra tegretol to keppra teaspoon or tablespoon is not an adequate measuring device. It measuring.

given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 tegretol to keppra additional every tegretol to keppra weeks) to 2.